CLRB - Cellectar Biosciences, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

CLRB

CELLECTAR BIOSCIENCES, INC.

NASDAQ

$1.45

▲ UP 3.57% (0.05)

KEY STATISTICS

Market Cap$11.11 M

52w High$5.07

52w Low$1.34

Dividend Yield—

Frequency—

P/E-0.22

Volume91.47K

Shares Out.7.99M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

James V. Caruso

COMPENSATION 2026

Salary$676,000

Stock Awards$0

Incentive Plan Pay$169,000

All Other Comp.$0

Total$1,055,600

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 10, 2005

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$11.00

Target Low$11.00

Target Median$11.00

Target Consensus$11.00

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$17.00M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-06-24	Reverse	1:30
2025-06-23	Reverse	1:30
2022-07-22	Reverse	1:10
2022-07-21	Reverse	1:10
2018-07-17	Reverse	1:10
2018-07-16	Reverse	1:10
2016-03-07	Reverse	1:10
2016-03-06	Reverse	1:10
2014-06-20	Reverse	1:20
2014-06-16	Reverse	1:20

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

VTS.AX

0.00%

184.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED

35.66%

HOLDERS

TOP 8 OF 27 · RANKED BY POSITION SIZE

Marxe Austin W & Greenhouse David M

Virtu Kcg Holdings LLC

64.9K sh

$106K

Geode Capital Management, LLC

52.8K sh

$134.06K

Raymond James Financial Services Advisors, Inc.

30.0K sh

$64.2K

Act Capital Management, LLC

21.8K sh

$73K

PRICE

$1.45 ▲ UP 3.57% (+$0.05)

OVERLAYS

About Cellectar Biosciences, Inc.

https://www.cellectar.com ↗

Cellectar Biosciences is a biopharmaceutical company developing cancer treatments, with lead drug CLR 131 in multiple Phase 2 trials for hematologic and pediatric cancers, and other PDC programs in preclinical or collaborations.

INDUSTRY

Biotechnology

A PRODUCT CELLECTAR BIOSCIENCES, INC. IS KNOWN FOR

Iopofosine I 131

Iopofosine I 131 is a targeted radiation therapy PDC for Waldenstrom's macroglobulinemia, FDA Breakthrough Therapy Designation, showing promise as a first-in-class treatment.

Cellectar Biosciences in 2025

SENTIMENT: + POSITIVE

REGULATORY · JUNE 4, 2025

Cellectar Biosciences Granted FDA Breakthrough Therapy Designation for Iopofosine I 131, Sparking Significant Stock Surge

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Cellectar's lead drug candidate, iopofosine I 131, for the treatment of Waldenstrom Macroglobulinemia (WM). This designation, supported by positive Phase 2 clinical trial data, is intended to expedite the development and review of drugs for serious or life-threatening conditions and was a major validation of the drug's potential.

LEADERSHIP STRATEGY · APRIL 2025 · IN PROGRESS

Cellectar Biosciences Initiates Exploration of Strategic Alternatives to Maximize Shareholder Value

In a pivotal move, Cellectar Biosciences announced that its leadership has commenced a comprehensive review of strategic alternatives. This process is aimed at advancing its radiopharmaceutical drug development pipeline and maximizing stockholder value, with options under consideration including mergers, acquisitions, strategic partnerships, joint ventures, and licensing agreements.